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Introduction {#sec1}
============

The p53 tumor suppressor is a key protein involved in the cellular network of different types of cellular stress ([@bib58]) and the most frequently mutated gene in human cancer ([@bib5], [@bib45]). In response to DNA damage, oncogene activation, genotoxicity, abnormal growth signals, and hypoxia, the active tetrameric form of this protein functions as a transcription factor that regulates the expression of a large group of responsive genes involved in apoptosis, cell-cycle arrest and survival, DNA repair, genomic stability, and senescence ([@bib58]). TP53 mutations are associated with tumor development, and some result in p53 loss and gain of function and have a dominant-negative effect, which affects cell survival ([@bib3], [@bib24], [@bib36], [@bib71], [@bib72], [@bib74]).

Seminal *in vitro* biophysical studies have shown that the core domain of p53 (p53C) aggregates into a mixture of oligomers and fibrils ([@bib29]). Additionally, a hotspot mutant of p53C (R248Q) was shown to seed the aggregation of the wild-type (wt) form of p53 *in vitro*, a typical behavior of a prion-like protein ([@bib3], [@bib53]). Further models support the existence of coaggregation with other transcription factors ([@bib62]). Nevertheless, previous studies have revealed the occurrence of cell-to-cell transmissibility events involving p53 ([@bib21], [@bib37], [@bib38]), which supports the suggested prion-like nature of this tumor suppressor. The ability of p53 to aggregate comes from its thermodynamic instability, which causes p53 to unfold near physiological temperatures ([@bib7]). More importantly, conformational changes in wt-p53C (the DNA-binding domain of p53) generate an aggregation-competent state, ultimately causing p53 aggregation inside the cell, which has implications for cancer establishment ([@bib49]). For example, *in vitro* studies using the fluorescence of p53C have shown the presence of wt-p53C molten globule states prone to amyloid aggregation ([@bib49]). In the same vein, characterization of p53 molten globule structures under mildly acidic treatment *in vitro* showed they were present in lysosomal compartments ([@bib6]). NMR spectroscopy revealed molten globule-like features of p53C in association with heat shock protein 90 (Hsp90) ([@bib48]). Furthermore, different aggregation phenotypes were observed in biopsies of breast tumor ([@bib39]) and cell lines of different cancers, including breast ([@bib3]), ovarian ([@bib72]), and prostate cancers ([@bib34]), supporting the hypothesis that p53 undergoes misfolding prior to amyloid aggregation in these cells. The typical p53 pathway is controlled by the p53-MDM2 axis, triggering the proteasome-dependent degradation of p53 and surveillance by a negative feedback loop, in which p53 stimulates MDM2 transcription ([@bib4], [@bib44], [@bib69]). Although mutant p53 is degraded through the p53-MDM2 regulatory axis, MDM2 transcription feedback is lost, a condition that favors the escape of mutant p53 and its accumulation within the cell ([@bib43]). Conceivably, the p53 structural instability and deregulation of the intracellular mutant p53 favor a condition in which conformational changes and oligomeric p53 compositions might occur, supporting oncogenic activities. Therefore, identification and analyses of the oncogenic activities in living cells related to multimeric/oligomeric mutant p53 species are urgently needed.

Glioblastoma is the most frequent, aggressive, and invasive type of brain tumor ([@bib22], [@bib47]). The hallmarks of glioblastoma are uncontrolled cellular proliferation, diffuse infiltration, a propensity for necrosis, robust angiogenesis, strong resistance to apoptosis, and rampant genomic instability ([@bib42]). Primary and secondary glioblastoma are disease subtypes with different genetic features. A total of 90% of cases are diagnosed as primary glioblastoma without previous clinical or histological evidence ([@bib63]). Approximately 30% of primary glioblastomas show TP53 mutations associated with gain-of-function, loss-of-function, and dominant-negative effects ([@bib26], [@bib41], [@bib65], [@bib64]). p53 accumulates in the cytoplasm of primary glioblastoma cells, suggesting its role in tumor pathogenesis ([@bib46]). Notably, the M237I-p53 mutation is present in 0.63% of cancer samples (as cataloged by the International Agency for Research on Cancer, IARC). Human lymphoblast cell lines containing this mutation showed delayed X-ray-induced apoptosis ([@bib70]) and increased chemosensitivity to temozolomide (TMZ) in glioblastoma cells after p53 knockdown ([@bib64]), supporting a chemoresistance gain-of-function phenotype. Previous studies have indicated that p53 regulates the expression of the MGMT gene encoding the O^6^-methylguanine DNA-methyltransferase protein in fibroblasts and astrocytes. In glioblastoma cells bearing the M237I p53 mutation, p53 knockdown leads to a 5-fold increase in chemosensitivity to TMZ ([@bib64]). The MGMT protein repairs DNA damage caused by TMZ, indicating a potential p53-dependent drug resistance mechanism. This tumor-associated mutation occurs within the Zn^2+^-binding site motif at loop 3 of p53 and drastically affects the p53 DNA-binding ability ([@bib8]). To the same extent as the hotspot mutation R175H, M237I is a destabilizing mutation that has been shown to increase solvent accessibility ([@bib8]). No mechanistic investigation has assessed the impact of increased solvent accessibility and hydration on chemoresistant p53 mutants and the consequences for protein oligomerization and p53 malignant transformation.

Here, we investigated the aggregation phenotype of a chemoresistant p53 mutant in glioblastoma cells and the ability of the mutation to promote the formation of p53 multimers that can potentially aggregate in living cells. We discovered insights into the existence of amyloid-like mutant p53 species in brain tumor cells presenting a chemoresistance gain-of-function phenotype and the distribution of mutant p53 multimers larger than the active tetrameric form of p53 in living cells. Furthermore, the destabilized mutant is found in non-native species in solution, which progressively leads to protein misfolding and amyloid aggregation. We found that increased hydration of the mutant leads to an increased tendency to aggregate. The development of personalized screening to map how tumor-associated p53 mutations affect folding, aggregation, and the malignant oncogenic phenotype of p53 is of fundamental importance toward developing therapies to avert cancer.

Results {#sec2}
=======

Amyloid Oligomers of a Chemoresistance p53 Mutant Accumulate in Glioblastoma Brain Cell Tumors {#sec2.1}
----------------------------------------------------------------------------------------------

Chemoresistance related to aberrant p53 involves the regulation of several target genes. We confirmed the increased RNA levels of MGMT and phosphatase and tensin (PTEN) ([Figures S1](#mmc1){ref-type="supplementary-material"}A--S1C) and the increased cell motility (migration rate) upon scratch formation ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E) in T98G glioblastoma cells expressing a p53 protein with Met-to-Ile substitution at position 237 of p53 compared with wt-p53-expressing U87 glioblastoma cells. Furthermore, we observed increased chemosensitivity to TMZ treatment in cells expressing wt-p53 compared with cells expressing the M237I-p53 mutant ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Evaluating the transcriptional profile, we detected decreased p53 and PTEN RNA levels after 48 h of TMZ treatment in wt-p53-expressing cells but observed no changes in the p53 and PTEN RNA levels in glioblastoma cells carrying the M237I mutation ([Figures S1](#mmc1){ref-type="supplementary-material"}G and S1H). MGMT was transcribed at higher levels during TMZ treatment in T98G cells than in wt-p53-expressing cells, in which MGMT transcription was undetectable within the studied time period ([Figure S1](#mmc1){ref-type="supplementary-material"}G). These results support previous findings indicating a chemoresistance phenotype in T98G glioblastoma cells and linking the Met-to-Ile p53 substitution to this gain-of-function phenotype.

To evaluate whether aggregation of mutant and wt-p53 has a role in the chemoresistance phenotype of glioblastoma-derived cells, we performed immunofluorescence experiments using confocal microscopy ([Figures 1](#fig1){ref-type="fig"}A--1P and [S2](#mmc1){ref-type="supplementary-material"}A--S2P) of one commercial glioblastoma cell line carrying the wt-p53 sequence (U87, [Figures 1](#fig1){ref-type="fig"}A--1D), one noncommercial cell line obtained from a deceased patient with glioblastoma (GBM11, [Figures 1](#fig1){ref-type="fig"}E--1H), and two glioblastoma cell lines carrying p53 DNA-binding domain mutations; U138 cells carry the hotspot R273H mutation ([Figures 1](#fig1){ref-type="fig"}I--1L), and T98G cells exhibit TMZ chemoresistance through the M237I mutation ([Figures 1](#fig1){ref-type="fig"}M--1P). DNA sequencing of the U87, T98G, and GBM11 cells revealed that the TP53 genes of the U87 and GBM11 cells carried no mutations in the protein DNA-binding domain, in contrast to T98G cells, in which a codon change (ATG-to-ATA) at position 237 causing a Met-to-Ile substitution was confirmed ([Figure S3](#mmc1){ref-type="supplementary-material"}).Figure 1p53 Amyloid Oligomerization in Chemoresistant Glioblastoma Cells(A--P) Immunofluorescence panels for (A--D) wt p53-expressing (U87), (E--H) wt p53-expressing (GBM11), (I--L) R273H p53-expressing (U138), and (M--P) M237I p53-expressing (T98G) glioblastoma cells showing p53 colocalization (white arrows) with amyloid oligomers. Scale bars, 20 μm; (Q--X) Immunofluorescence panels for (Q) wt p53-expressing (U87), (R) wt p53-expressing (GBM11), (S) R273H p53-expressing (U138), and (T) M237I p53-expressing (T98G) glioblastoma cells showing merged p53 and amyloid oligomer channels used for pixel-by-pixel quantification. (U--X) Pixel-by-pixel correlation plots between p53 and oligomer channels. Regions 1, 2, and 3 were classified as +/−, −/+, and +/+ (p53/oligomers). Pixel frequency is color coded. Pixels within the double-positive region 3 indicate colocalization between p53 and oligomers. Three independent immunofluorescence experiments were performed with similar results. See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

We observed weak immunostaining for wt-p53 in U87 cells ([Figures 1](#fig1){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A). Controversially, for wt-p53 in GBM11 cells, diffuse immunostaining in the cytosol and stronger labeling in the nuclei were observed ([Figures 1](#fig1){ref-type="fig"}E and [S2](#mmc1){ref-type="supplementary-material"}E). These wt-p53-expressing cells exhibited slight colocalization of p53 with oligomeric structures ([Figures 1](#fig1){ref-type="fig"}D and 1E), and most of the colocalized structures were located at the nuclei or in the perinuclear region ([Figures 1](#fig1){ref-type="fig"}D, 1E, [S2](#mmc1){ref-type="supplementary-material"}C, S2D, S2G, and S2H). The T98G cells exhibited more colocalization of oligomeric structures and M237I-p53 in the nuclei and the perinuclear region ([Figures 1](#fig1){ref-type="fig"}M, [S2](#mmc1){ref-type="supplementary-material"}O, and S2P) than U138 cells ([Figures 1](#fig1){ref-type="fig"}I--L, [S2](#mmc1){ref-type="supplementary-material"}K, and S2L), revealing that the M237I-p53 mutant assumes an aggregation-prone conformation that triggers amyloid oligomerization in this chemoresistant glioblastoma cell type. Notably, accumulated M237I-p53 amyloid oligomers seem to play a specific role in the chemoresistance phenotype of these cells, as the glioblastoma cells bearing the hotspot mutant showed negligible p53 aggregation ([Figures 1](#fig1){ref-type="fig"}I--L, [S2](#mmc1){ref-type="supplementary-material"}K, and S2L). The colocalization of oligomeric p53 was quantified pixel by pixel using the correlation between the fluorescent channels in different confocal images ([Figures 1](#fig1){ref-type="fig"}Q--1Y, [S2](#mmc1){ref-type="supplementary-material"}Q--S2Z, and S2AA--S2FF) and Pearson\'s coefficient ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4Q). A high number of pixels within the double-positive region (labeling number three) of the correlation plots indicates strong colocalization between p53 and amyloid oligomers in GBM11 ([Figures 1](#fig1){ref-type="fig"}R and 1V) and T98G ([Figures 1](#fig1){ref-type="fig"}T and 1Y) cells; however, the correlation between both channels (diagonal distribution of pixels) was more pronounced in glioblastoma cells expressing the M237I-p53 mutant than in those expressing wt-p53 ([Figures 1](#fig1){ref-type="fig"}T, 1Y, [S2](#mmc1){ref-type="supplementary-material"}EE, and S2FF).

One typical feature of aggregated assemblies is their resistance to harsh treatments. To further support the existence of aggregated species composed of mutant p53 in T98G cells, we subjected the overall protein fraction extracted from T98G cells to p53 immunoprecipitation followed by SDS-denaturing gels and immunoblots to detect p53. We observed SDS-resistant, high-molecular-weight mutant p53 species using this approach ([Figure S5](#mmc1){ref-type="supplementary-material"}A). In addition, we observed a diffuse band at approximately 37 kD, which likely represented proteolytic M237I p53 fragments. In addition, whole H1299 and T98G cell extracts were subjected to size exclusion chromatography ([Figure S5](#mmc1){ref-type="supplementary-material"}B), and eluted fractions were assessed by dot blots to detect p53 species ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Eluted fractions from T98G cells corresponding to the column void volume showed positive immunostaining for p53 species ([Figure S5](#mmc1){ref-type="supplementary-material"}C), confirming the presence of high-molecular-weight p53 assemblies in this glioblastoma cell type.

Excess Formation of Mutant p53 Species Sustains Aggregation in Glioblastoma Cells {#sec2.2}
---------------------------------------------------------------------------------

As protein accumulation favors misfolding and ultimately aggregation and cell deregulation, we evaluated the p53 RNA and protein levels in glioblastoma cells expressing wt (U87 and GBM11) and mutant (U138 and T98G) p53 ([Figures 2](#fig2){ref-type="fig"}A--2D and [S6](#mmc1){ref-type="supplementary-material"}). Surprisingly, we observed increased p53 expression at both the RNA and protein levels in the chemoresistant M237I-p53-expressing cells ([Figures 2](#fig2){ref-type="fig"}A--2D). As shown in [Figure 2](#fig2){ref-type="fig"}A, the p53 RNA levels in mutant p53-expressing cells (U138 and T98G) were higher than those in wt-p53-expressing cells (U87 and GBM11). Densitometric values ([Figures 2](#fig2){ref-type="fig"}B and 2D) for the p53 RNA and protein levels were expressed in correlation plots in which the p53 protein/RNA levels in T98G cells were different from those in the other cells, suggesting p53 deregulation at the protein level ([Figure 2](#fig2){ref-type="fig"}E). The levels of M237I-p53 in T98G cells were 27.2% higher than M237I-p53 RNA levels, suggesting p53 accumulation in these cells. To further confirm M237I-p53 oligomeric species in this chemoresistant cell line, we performed immunoprecipitation of whole U87 and T98G cell extracts using an oligomer-sensitive antibody followed by p53 immunoblot detection. The results revealed stronger p53 immunostaining in T98G than U87 cells ([Figures 2](#fig2){ref-type="fig"}F and [S6](#mmc1){ref-type="supplementary-material"}) consistent with the immunofluorescence results ([Figures 1](#fig1){ref-type="fig"}D and 1M).Figure 2Accumulation of M237I-p53 in Glioblastoma Cells(A) Agarose strips showing the p53 RNA levels in glioblastoma and H1299 cells.(B) Dot plots showing densitometry values obtained after normalizing p53 transcriptional levels to those of glyceraldehyde 3-phosphate dehydrogenase, GAPDH. The results are shown as the mean ± SEM of three densitometry measurements. Experiments were performed twice with similar results (\*\*\*U87 versus U138, p = 0.0005; \*\*\*U87 versus T98G, p= 0.0002; \*\*p= 0.0012, and ns not significant).(C) Immunoblots (IBs) showing total p53 levels (DO-1) and β-actin as a loading control.(D) Dot plots showing densitometry values obtained after normalizing p53 protein levels to those of actin. The results are shown as the mean ± SEM of three densitometry measurements. Experiments were performed twice with similar results (\*\*\*\*p\< 0.0001, \*p= 0.0365).(E) Correlation plot of p53 RNA versus p53 protein levels in glioblastoma and H1299 cells. (F) Immunoblots (IBs) showing total p53 levels (input) and the levels of oligomeric p53 in T98G cells after immunoprecipitation (IP) with an oligomer-sensitive antibody (A11).See also [Figure S6](#mmc1){ref-type="supplementary-material"}. kD refers to the expected weight of the detected proteins in kilodaltons.

To investigate whether the increased M237I-p53 accumulation is potentially related to the presence of unfolded p53 species and ER stress, we detected the protein levels of two unfolded protein response (UPR) sensors, inositol-requiring protein-1a (IRE-1α), and protein kinase RNA-like ER kinase (PERK). In contrast to U138 and GBM11 cells, T98G cells expressed detectable levels of the IRE-1α and PERK sensors, as shown by immunoblots ([Figures S7](#mmc1){ref-type="supplementary-material"}A--S7D). Notably, U87 cells showed significantly higher levels of these UPR sensors than other cells, but as the p53 level was negligible, ER stress cannot be attributed to wt-p53 overload in this cell line. Furthermore, we detected equally higher Hsp90 levels in both the M237I-p53-expressing cells and U87 cells expressing wt-p53 than the Hsp90 levels in the other studied cells ([Figure S7](#mmc1){ref-type="supplementary-material"}D). Altogether, the accumulation of M237I-p53 ([Figure 2](#fig2){ref-type="fig"}) species in glioblastoma cells and the presence of amyloid p53 oligomers ([Figures 1](#fig1){ref-type="fig"}, [S2](#mmc1){ref-type="supplementary-material"}, and [S4](#mmc1){ref-type="supplementary-material"}) potentially link oligomeric p53 mutant compositions to chemoresistance gain-of-function activity in glioblastoma.

The Mutant p53 Oligomer Composition in Living Cells {#sec2.3}
---------------------------------------------------

Because M237I-p53 forms amyloid oligomers in glioblastoma cells expressing a chemoresistance gain-of-function phenotype, we decided to explore the oligomer composition and distribution of this mutant in living cells. We first detected the different distributions of the EGFP-tagged wt-p53 and M237I-p53 constructs in H1299 cells ([Figure S8](#mmc1){ref-type="supplementary-material"}). Next, using systematic number and brightness (N&B) analysis of fluorescence fluctuation spectroscopy data, we directly measured the wt- and M237I-p53 oligomerization status and distribution within living cells. To exclude any interference from endogenous p53 aggregation, we used p53-null H1299 lung carcinoma cells. N&B statistical analysis provides a pixel-by-pixel resolution map of the molecular oligomers in living cells by measuring the average intensity and variance in each pixel in a time series of images ([@bib13], [@bib14]) ([Figures 3](#fig3){ref-type="fig"}A, [S9](#mmc1){ref-type="supplementary-material"}A, and S9B). From these values, the apparent brightness (B maps) and average number of molecules (N maps) can be estimated (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}). During the acquisition of image frames, the laser power was set accordingly to eliminate a contribution from photobleaching (see [Transparent Methods](#mmc1){ref-type="supplementary-material"} and [Figures S9](#mmc1){ref-type="supplementary-material"}C and S9D). The brightness maps directly report the oligomerization status of proteins, as larger particles generate higher fluorescence fluctuation as they pass in and out of the excitation volume, resulting in higher variance. Thus, the higher the apparent brightness is, the higher the oligomerization status is, and the fewer molecules there are within the excitation volume.Figure 3Detection of p53 Oligomers in Living Cells(A) Representative frames of an EGFP-transfected H1299 imaged cell used as input for statistical number and brightness (N&B) analysis.(B) Representative intensity, brightness (B), and number of molecule (N) maps of an EGFP-transfected H1299 imaged cell.(C--E)(C) Selection of pixels within brightness plots (red and green squares) (D) or from Gaussians (red and green) of brightness distribution, which can be used to (E) depict their distribution in imaged cells. Red colors correspond to the immobile fraction (background), and green pixels correspond to monomeric EGFP.(F--I) (F and G) and (H and I), Brightness plots of M237I-p53 and wt-p53, respectively, showing different brightness distributions. Intensity, B, and N maps of imaged (F and G), M237I-p53- and (H and I) wt-p53-expressing cells highlighting bright pixels indicating M237I-p53 within the nuclei (white arrows). Puncta of wt-p53, in which an increased number of molecules in N maps do (green arrows) or do not (red arrows) overlap with bright pixels are shown. Red pixels in the bottom right panels of imaged cells represent cytosolic (red) and nuclear (green) p53 distribution according to Gaussian brightness histograms. All N&B experiments were performed at least twice with similar results.See also [Figures S9--S11](#mmc1){ref-type="supplementary-material"}.

To compare wt and mutant p53 oligomeric states within living cells, we first normalized the brightness levels of the monomeric EGFP standard ([Figures 3](#fig3){ref-type="fig"}A--3E). We obtained an average B value for monomeric EGFP of 1.21 (n = 7 imaged cells, [Figures 3](#fig3){ref-type="fig"}C--3E and [S10](#mmc1){ref-type="supplementary-material"}). Cells transfected with EGFP showed a homogeneous distribution of monomeric EGFP throughout the whole cell ([Figures 3](#fig3){ref-type="fig"}D, [S10](#mmc1){ref-type="supplementary-material"}, and [S11](#mmc1){ref-type="supplementary-material"}A). Based on the normalized B value of monomeric EGFP, the oligomeric status and distribution of M237I-p53-EGFP-transfected ([Figures 3](#fig3){ref-type="fig"}F, 3G, and [S12](#mmc1){ref-type="supplementary-material"}A) and wt-p53-EGFP-transfected ([Figures 3](#fig3){ref-type="fig"}H, 3I, and [S12](#mmc1){ref-type="supplementary-material"}B) cells were evaluated. Brightness plots of M237I-p53-transfected ([Figures 3](#fig3){ref-type="fig"}F and 3G) and wt-p53-transfected ([Figures 3](#fig3){ref-type="fig"}H and 3I) cells revealed distinctly different distributions (n = 10 imaged cells, [Figures 3](#fig3){ref-type="fig"}, [S11](#mmc1){ref-type="supplementary-material"}B, S11C, and [S12](#mmc1){ref-type="supplementary-material"}). M237I-p53-transfected cells exhibited pixels with higher B values than those of wt-p53-transfected cells ([Figures 3](#fig3){ref-type="fig"}F--3I and [S12](#mmc1){ref-type="supplementary-material"}). B maps of the imaged cells showed that 9 of 10 M237I-p53-transfected cells had brighter pixels than wt-p53-transfected cells either within the nuclei or throughout the entire cytosol ([Figures 3](#fig3){ref-type="fig"}F--3I and [S11](#mmc1){ref-type="supplementary-material"}C, white arrows). In contrast, wt-p53-transfected cells showed a more homogeneous B map distribution than M237I-p53-transfected cells ([Figures S11](#mmc1){ref-type="supplementary-material"}B and S11C), which is similar to the findings in monomeric EGFP-transfected cells ([Figure S11](#mmc1){ref-type="supplementary-material"}A). Among 10 imaged wt-p53-transfected cells, one exhibited brighter pixels within the nuclear region than the imaged M237I-p53-transfected cells ([Figure S11](#mmc1){ref-type="supplementary-material"}B, red asterisk). Interestingly, the distribution of abundant wt-p53 molecules confined within cytosolic puncta does not predominantly overlap with the bright pixel regions ([Figures 3](#fig3){ref-type="fig"}F--3I, [S11](#mmc1){ref-type="supplementary-material"}B, and [S12](#mmc1){ref-type="supplementary-material"}, red arrows), although this finding was not true in all cases ([Figures 3](#fig3){ref-type="fig"}F--3I and [S11](#mmc1){ref-type="supplementary-material"}B, green arrows). Most of the wt-p53 molecules within the puncta overlapped with bright pixels corresponding to assemblies of higher-order aggregates with B values in the range of 3--4 ([Figure S13](#mmc1){ref-type="supplementary-material"}). In M237I-p53-expressing cells, puncta formation was not observed in the imaged cells and the increased number of M237I-p53 molecules within the nuclei predominantly overlapped with bright pixels.

To precisely assess the distinct oligomer composition and distribution of wt- and M237I-p53 in living cells, we used the normalized apparent brightness of monomeric EGFP (B value standard = 1.2) and the following equation: B = εn + 1 (see [Transparent Methods](#mmc1){ref-type="supplementary-material"}) and estimated B values of 1.4 and 1.8 for p53 dimers and tetramers, respectively. This implies that B values higher than 2 correspond to species larger than p53 tetramers. We used rectangular slices in brightness plots to indicate the brightness of monomeric ([Figures 4](#fig4){ref-type="fig"}A--4F, red), dimeric ([Figures 4](#fig4){ref-type="fig"}G--4L, green), and tetrameric ([Figures 4](#fig4){ref-type="fig"}M--4R, blue) wt- and M237I-p53 molecules and the brightness levels for M237I-p53 oligomers ([Figures 4](#fig4){ref-type="fig"}S--4U, orange). Pinpointing selected pixels with different B levels in the imaged cells allowed us to make important conclusions about the distribution and behavior of wt- and M237I-p53 oligomers. M237I-p53 showed very low cytosolic B levels corresponding to monomers and dimers, in contrast to the pronounced cytosolic distribution of M237I-p53 tetramers ([Figures 4](#fig4){ref-type="fig"}V--4W). Surprisingly, most B values corresponding to oligomeric M237I-p53 molecules (at least larger than tetramers) were widely distributed within the nuclei and less densely distributed throughout the cytosolic region ([Figures 4](#fig4){ref-type="fig"}V--4W, white arrowheads). Meanwhile, wt-p53 B values corresponding to monomers and dimers were predominant, and wt-p53 was mostly distributed throughout the entire cell, whereas tetramers were extremely sparse ([Figures 4](#fig4){ref-type="fig"}Y--4AA). Altogether, these results provide direct evidence of mutant p53 oligomers (larger than tetrameric p53) within the nuclei of living cells. More important, the mutant p53 used in these studies forms amyloid oligomers in glioblastoma cells that present a chemoresistance gain-of-function phenotype, a condition conducive to the formation of misfolded species.Figure 4The Composition of Mutant p53 Oligomers in Living Cells(A--U) Selection of pixels showing the brightness levels of M237I- and wt-p53 (A--F) monomers (red), (G--L) dimers (green), (M--R) tetramers (blue), and (S--U) M237I-p53 oligomers (orange).(V--AA) Distribution of selected pixels in imaged cells expressing (V--W) M237I-p53 and (Y--AA) wt-p53. White arrowheads highlight the predominant distribution of M237I-p53 oligomers in cellular nuclei. The same color code is used to report oligomeric states throughout the figure. All N&B experiments were performed at least twice with similar results.See also [Figures S12](#mmc1){ref-type="supplementary-material"} and [S13](#mmc1){ref-type="supplementary-material"}.

Increased Hydration Explains the Reduced Structural Integrity and Amyloid Oligomerization of Mutant p53 {#sec2.4}
-------------------------------------------------------------------------------------------------------

To identify the structural determinants causing the distinct composition of mutant p53 oligomers in cells, we performed *in vitro* and structural analyses. Met237 is located at the beginning of the L3 loop close to the Zn^2+^-binding site, which is similar to the location of the hotspot mutation R175H ([Figure S14](#mmc1){ref-type="supplementary-material"}A). The S-methyl thioether side chain of Met237 is in close proximity to the His179 imidazole group participating in the Zn^2+^ coordinate sphere ([Figure S14](#mmc1){ref-type="supplementary-material"}A). Evaluation of wt- and M237I-p53 hydrophobicity maps revealed that the small increase in hydrophobicity within the mutant p53 Zn^2+^-binding site explains its destabilization ([Figure 5](#fig5){ref-type="fig"}A). *In silico* mutagenesis showed that, for correct accommodation, the bulky isoleucine side chain must move away from the Zn^2+^-binding site to avoid clashes ([Figures 5](#fig5){ref-type="fig"}A and [S14](#mmc1){ref-type="supplementary-material"}A). This situation potentially impacts the Met237-Cys238-Zn^2+^ hydrophobic environment and proper zinc coordination within the L2-L3 interface loops. Furthermore, a stabilizing H-bond occurring between Met237 and Leu194, which is located at the base of loop L2, is disrupted by amino acid substitution. Because Zn^2+^ has a structural role in p53 and the hydrophobic environment of Met237 seems to promote proper Zn^2+^ accommodation, we performed guanidine hydrochloride titrations and detected the fluorescence of intrinsic p53 probes to determine the structural stability of recombinantly expressed M237I-p53C compared with that of wt-p53C ([Figures 5](#fig5){ref-type="fig"}B and 5C). The concentration of guanidine at the midpoint of the folding transition (G~50%~) was approximately 0.7 and 1 M for M237I-p53C and wt-p53C, respectively, confirming the structural role of M237 in maintaining the p53 structural stability ([Figures 5](#fig5){ref-type="fig"}C and [S14](#mmc1){ref-type="supplementary-material"}B). This mutation affects the conformational ensemble of M237I-p53C native states (N), as the M237I-p53C Tyr fluorescence emission spectra was 60% less intense than that measured for wt-p53C ([Figure 5](#fig5){ref-type="fig"}D). As the solvent polarity was equal in these measurements, the most likely explanation for the pronounced reduction in intensity is the dipolar reorientation of p53 Tyr probes upon excitation due to increased protein hydration.Figure 5Hydrated Mutant p53 States Lead to Aggregation(A) Hydrophobic maps highlighting increased hydrophobicity within the Zn^2+^-binding structural motif after Ile237 introduction. (PDB: [2FEJ](pdb:2FEJ){#interref15})(B) Schematics showing intrinsic tyrosine (green spheres) and single tryptophan (red spheres) fluorescent probes used to report conformational changes in the p53 DNA-binding domain. Methionine 237 is highlighted in orange. (PDB:[2FEJ](pdb:2FEJ){#interref20})(C) Plot of the fraction of unfolded M237I-p53C and wt-p53C against increasing concentrations of guanidine hydrochloride (Gu-HCl).(D) Tyrosine fluorescence emission spectra of M237I- and wt-p53C.(E) Pressure jump experiments reporting light scattering (LS, top) and changes in the center of spectral mass of M237I- and wt-p53C. Increased LS measurements at atmospheric pressure represent values obtained after depressurizing the samples.(F and G) Collection of fluorescence emission spectra for (F) M237I-p53C and (G) wt-p53C, respectively.(H and I) Highlights in the different spectral regimens observed for (H) M237I-p53C and (I) wt-p53C, respectively.See also [Figures S14](#mmc1){ref-type="supplementary-material"}A and S14B. The results are shown as the mean ± SEM of at least three independent experiments.

To test the effects of hydration on the p53C domain and how hydration impacts the p53 Cys~3~-His~1~ Zn^2+^-binding motif, we designed pressure jump experiments reporting changes in the fluorescence of p53 intrinsic probes. Interestingly, M237I-p53C was more sensitive to pressure-induced treatment than wt-p53C ([Figure 5](#fig5){ref-type="fig"}E, bottom). The p~50%~ of M237I- and wt-p53C was approximately 1.6 and 2.6 kbar, respectively, confirming that the hydrophobic Met-to-Ile substitution within the Zn^2+^-binding motif triggers the formation of an ensemble of destabilized and hydrated structural conformers. The reduced intensity of the Tyr residues at atmospheric pressure in M237I-p53C indicates the movement of these residues to a more hydrated environment with no predominant loss of tertiary structure, as no redshift was observed within the emission spectra ([Figure 5](#fig5){ref-type="fig"}D). The hydrophobic introduction of Ile237 within the Zn^2+^-binding structural motif was sufficient to create an ensemble of destabilized and hydrated conformers prone to amyloid aggregation. If true, it is reasonable to claim that M237I-p53C contains exposed hydrophobic patches. More interesting is the identification of different emission spectral regimens for M237I-p53C ([Figure 5](#fig5){ref-type="fig"}F) and wt-p53C ([Figure 5](#fig5){ref-type="fig"}G). We are aware that the ensemble of M237I-p53C structural conformers (hereafter called N∗) is not the same as the wt-p53C native ensemble (hereafter called N) but is instead composed of a broad population of destabilized native-drifted states exhibiting increased hydration. In contrast to the spectral regimen observed for wt-p53C, we identified four spectral regimens for M237I-p53C. The first regimen was common to M237I-p53C (up to 1.4 kbar) and wt-p53C (up to 2.7 kbar), in that there was no appreciable difference in the Tyr emission spectra between the M237I-p53C N∗ and wt-p53C N states ([Figures 5](#fig5){ref-type="fig"}H and 5I; first regimen). The destabilized and hydrated M237I-p53C N∗ states behaved differently from the wt-p53C N states within a range between 1.4 and 2.2 kbar. The N∗ states exposed a single Trp residue, a clear indication of protein unfolding ([Figure 5](#fig5){ref-type="fig"}H; second regimen). Based upon the exposure of the p53 intrinsic probes, pressure-induced unfolding of wt-p53C N states did not occur, and spectral signals moved directly to the fourth regimen, in which protein aggregation occurred ([Figure 5](#fig5){ref-type="fig"}I; fourth regimen). Aggregation was shown by the increased scattering contribution within the 300- to 310-nm range ([Figure 5](#fig5){ref-type="fig"}I; fourth regimen) and confirmed by light scattering (LS) measurements ([Figure 5](#fig5){ref-type="fig"}E, top). Full unfolding of the M237I-p53 N∗ states was achieved between 2.2 and 2.9 kbar when the spectral signals reached a plateau ([Figure 5](#fig5){ref-type="fig"}H; third regimen). This pressure range supports a population of unfolded-drifted species (U∗), as small increments in pressure led to aggregation ([Figure 5](#fig5){ref-type="fig"}H; fourth regimen and [Figure 5](#fig5){ref-type="fig"}E, top).

To demonstrate that the conformational changes observed in the destabilized non-native species result in amyloid aggregation, we measured the kinetics of M237I-p53C by scattering and thioflavin T (ThT). In contrast to what was observed for wt-p53C, M237I-p53C revealed a very short lag phase (∼20 s) followed by a sharp increase in both signals up to a plateau at ∼500 s ([Figures 6](#fig6){ref-type="fig"}A and 6B, [S14](#mmc1){ref-type="supplementary-material"}C, and S14D). In the case of wt-p53C, the lag phase was longer (∼250 s) than that of M237I-p53C and followed by a smooth increase in scatter and the ThT signal. Fitting the curves to first-order lag kinetics revealed higher rate constants for the M237I-p53C than wt-p53C ([Table 1](#tbl1){ref-type="table"}), suggesting the fast formation of a population of aggregation-competent M237I-p53C conformers at physiological temperature. The ThT fluorescence levels of M237I-p53C were significantly higher than those of wt-p53C, revealing increased levels of M237I-p53C amyloid-like species even though a mixture of amyloid-like forms and general aggregation (amorphous + amyloid) was present, as evidenced by LS ([Figures 6](#fig6){ref-type="fig"}C and 6D). Negative staining transmission electron microscopy showed higher-order assemblies similar to amyloid-like structures composed of the M237I-p53C ([Figure 6](#fig6){ref-type="fig"}E). Finally, by treating wt and M237I-p53C with mild concentrations of guanidine, we observed increased exposure of hydrophobic patches in M237I-p53C compared with that in wt-p53C ([Figure 6](#fig6){ref-type="fig"}F). Bis-ANS emission spectra showed increased M237I-p53C hydrophobic exposure both in the folded state and at approximately 50% unfolding ([Figures 6](#fig6){ref-type="fig"}G and 6H). These findings confirmed that, by perturbing overall p53 hydration and protein hydrophobicity to the solvent, the M237I substitution populates destabilized native-drifted species that are preamyloidogenic. Collectively, these findings support a model in which destabilized aggregation-prone species are formed and contribute to the distinct composition of an agglomeration of chemoresistance mutant p53.Figure 6Amyloid Aggregation of M237I-p53 in Solution(A and B) Normalized thioflavin T (ThT) fluorescence kinetics of (A) M237I- and (B) wt-p53C at physiological temperature. The k1 and k2 rate constants ([Table 1](#tbl1){ref-type="table"}) were obtained after fitting (black lines) the experimental points (red) using first-order lag kinetics.(C and D) Dot plots showing (C) ThT fluorescence and (D) light scattering (LS) values after kinetic traces for wt- and M237I-p53C, respectively.(E) Negative staining micrographs after kinetic traces for M237I- and wt-p53C. Insets show zoomed areas. Scale bars, 0.2 μm.(F) Dot plot reporting the fluorescence of bis-ANS and wt- and M237I-p53C hydrophobicity following exposure to the solvent under increasing concentrations of guanidine hydrochloride, Gu-HCl (0, 0.2, 0.4, 0.6, 0.8, 1, and 3 M). The results are shown as the mean ± SEM of at least three independent experiments (p\< 0.0001, folded wt-p53 versus folded M237I-p53 and wt-p53 G~50%~ versus M237I-p53 G~50%~).(G and H) bis-ANS fluorescence spectra of wt- and M237I-p53C proteins under (G) folded and (H) 50% unfolded (at the G~50%~) conditions, respectively.See also [Figures S14](#mmc1){ref-type="supplementary-material"}C and S14D.Table 1Kinetic Parameters according to First-Order Lag KineticsWT-p53CM237I-p53Ck~1~ (min^−1^)4.1×10^−4^± 3.7 × 10^−6^0.481 ± 0.007k~2~ (min^−1^)5.9×10^−3^±2.7 × 10^−4^2.371 ± 0.097

Discussion {#sec3}
==========

The aggregation phenotypes of p53 observed in breast, ovarian, and prostate tumors have been correlated with p53 dominant-negative and oncogenic gain-of-function activities ([@bib34], [@bib36], [@bib71]). However, there has been no information that p53 can form oligomeric species in glioblastoma tumors and that agglomeration is associated with chemoresistance oncogenic activity in this type of brain tumor. Here, we explored questions related to the chemoresistance phenotype involving p53 in glioblastoma with the following aims: (1) identify p53 amyloid oligomers in glioblastoma cells, (2) investigate the composition and distribution of chemoresistant mutant p53 oligomers in living cells, (3) determine whether misfolding is a prerequisite for aggregation in cells, and (4) determine the mechanism by which mutant p53 amyloid aggregation occurs in solution.

The chemoresistance phenotype to TMZ, the standard treatment for glioblastoma, has been linked to a p53-specific mutation in glioblastoma cells through the increased expression of O^6^-methylguanine DNA-methyltransferase (MGMT), an enzyme that repairs DNA damage caused by TMZ ([@bib64]). Accordingly, the homologous PTEN tumor suppressor was found to exert oncogenic effects in mutant p53-expressing glioblastoma cells, including cell cycle progression, cell proliferation, and cell death inhibition ([@bib40]). Compared with those in wt p53-expressing glioblastoma cells, significantly higher transcript levels of MGMT and PTEN and faster migration in glioblastoma cells with the M237I-p53 mutation that are insensitive to TMZ were detected. The increased MGMT and PTEN transcript levels in T98G cells support their oncogenic transformation, which is reflected by the acquisition of phenotypes such as chemoresistance and acceleration of cell proliferation and migration.

Several lines of evidence have indicated that amyloid-like p53 oligomers are present in different tumor cells and tissues, as shown by using an amyloid oligomer-sensitive antibody ([@bib3], [@bib24], [@bib39]). The TMZ-chemoresistant glioblastoma cells showed higher levels of mutant p53 amyloid oligomers than glioblastoma cells expressing either wt p53 or a hotspot p53 mutant not associated with chemoresistance. Abnormal accumulation of wt and mutant p53 was described in different types of cancer cells, such as neuroblastoma, retinoblastoma, breast cancer, and colon cancer cells ([@bib34], [@bib39]). However, the levels of accumulated wt p53 and p53 mutants drastically differ, with significantly increased accumulation of the latter proteins. Aggregation of mutant p53 has been shown to impair the tumor suppressor activities of p53 and contribute to the gain of oncogenic phenotypes including chemoresistance. In high-grade serous ovarian carcinoma, p53 aggregation is related to platinum resistance ([@bib72]). Our findings link TMZ chemoresistance in glioblastoma to a mutant-specific p53 aggregation phenotype.

One of initial modifications required for dissociation of the p53 negative regulator MDM2 and activation of transcriptional activity is p53 phosphorylation at Ser15 ([@bib15], [@bib51]). Furthermore, cellular homeostasis is dictated by protein synthesis, degradation, and repair. When protein folding efficiency is threatened owing to protein overload within the ER, cells experience ER stress and activate the UPR ([@bib27], [@bib61]). If mutant p53 production exceeds the rates at which ER quality checks manage recently synthesized proteins, cells face a bottleneck in protein control. The expression of the two UPR sensors, inositol-requiring protein-1a (IRE-1a) and protein kinase RNA-like ER kinase (PERK), supports ER stress due to the overload of misfolded mutant p53 species. These two sensors participate in prosurvival signaling to eliminate misfolded species, reduce the transcription of mRNAs and increase the concentration of molecular chaperones to process accumulated proteins within the ER ([@bib28]).

Hsp90 is an ER-resident molecular chaperone that promotes proper folding and maturation of client proteins ([@bib73]). However, Hsp90 was previously shown to participate in the adaptive response of cancer cells by stabilizing and preventing degradation of overexpressed mutant p53 ([@bib19], [@bib66], [@bib67]). We speculate that Hsp90 might fail to chaperone the chemoresistance mutant p53, but the expression of equally high Hsp90 levels in U87 (wt-p53) and T98G cells indicate that other escape mechanisms may favor M237I accumulation and aggregation. Unfortunately, we were not able to rule out other potential escape mechanisms, such as impairment of the p53 degradation system. Hsp90 has been shown to chaperone recombinant wt p53 by positively modulating its DNA-binding ability at physiological temperatures ([@bib60]), and the DNA-binding domain of p53 adopts a molten globule-like state as it transiently binds to Hsp90 ([@bib48]). Recently, long-term Hsp90 inhibition was shown to extend the survival of R248Q p53-and R172H p53-expressing mice but not their corresponding p53(−/−) littermates ([@bib2]). Hsp90 and other cochaperones can also effectively distinguish wt p53 and mutant p53 conformations, as Hsp90 selectively binds to wt p53 but not to the hotspot mutant R175H p53, and other cochaperones are first required prior to the Hsp90-R175H p53 interaction ([@bib33]). The effects of p53 mutations on its structure may trigger a divergent chaperone cellular response impairing proper p53 turnover. In support of this finding, the Hsp90 inhibitor geldanamycin was previously shown to either stimulate cytoplasmic mutant p53 translocation into the nucleus or increase mutant p53 ubiquitination and proteasome-mediated degradation ([@bib66], [@bib67]). Notably, some destabilized mutant p53 proteins exhibit conformational changes that are sufficient to threaten chaperone activity and enhance aberrant stability.

The differences in the oligomer composition and localization of the wt and M237I p53 oligomers in living cells are also intriguing. Notably, the oligomeric species detected by N&B analysis in living cells are not necessarily the same as those amyloid oligomers revealed by immunofluorescence assays. Amyloid species detected by the oligomer-sensitive antibody are likely large species owing to their close association with chaperones or other p53 family members ([@bib71]). Meanwhile, those observed by N&B most likely represent the initial association steps of p53 multimers, such as octamers or limited multimers. In support of this finding, p53 octamers were recently shown to bind p53 response elements (REs) containing long spacers ([@bib59]). It is tempting to speculate that destabilized p53 mutations such as M237I would favor p53 octamers to form rapidly and bind to REs related to gain-of-function phenotypes. However, the identification of amyloid features of these initial multimers requires further investigation. We present evidence of oligomers consisting of a chemoresistant mutant p53 that are larger than the active p53 tetrameric form inside the nuclei of living cells ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}). Although a previous report using N&B analysis showed that the balance among wt p53 monomers, dimers, and tetramers is not determined simply by p53 concentration ([@bib23]), our results indicate that oligomers formed by cancer-associated mutations are concentration-dependent. In contrast to wt p53, for which we mostly detected monomers and dimers throughout the cytosol and nucleus, M237I p53 tetramers were abundant in the cytosol, and M237I p53 oligomers (at least those larger than tetramers) were densely distributed within the nucleus ([Figure 4](#fig4){ref-type="fig"}). As DNA damage was not chemically induced in our cells, we considered the imaged cells to be under resting conditions. Consistent with this finding, the distribution of wt p53 monomers and dimers conformed to previous estimations ([@bib23]). Surprisingly, M237I p53 tetramers were present in the cytosol. The tetramerization domain of p53, which contains a nuclear export signal (NES, residues 340--351), has been shown to be occluded as tetrameric p53 is formed, which forces p53 tetramers to remain in the nucleus ([@bib57]). According to this model, the monomeric and dimeric forms of p53 would have an exposed NES motif, allowing them to be shuttled to the cytosol. Based on our observations of M237I p53 tetramers in the cytosol, we speculated that M237I p53 dimers present in the cytosol adopt a conformation amenable to the formation of stable tetramers. Given the potential non-transcriptional roles of p53 ([@bib25]), the presence of functional mutant p53 tetramers in the cytosol of cancer cells may represent an unsolved conundrum that should be investigated. Furthermore, because the oligomerization status of p53 is linked to the cell fate, as p53 dimers show growth arrest but not apoptotic functions like tetramers ([@bib20]), the presence of p53 tetramers in the cytosol and larger oligomers in the nuclei of cancer cells may help us to understand the oncogenic activities in cancer. A recent contribution from the Prives group showed that the oligomerization status of p53 substantially impacts p53-MDM2 regulation and p53 localization, raising questions about how p53 tetramers are degraded ([@bib32]). The functionality of oligomers larger than tetramers in the nucleus is challenging to address, but based on previous works from our group ([@bib3], [@bib6], [@bib18], [@bib31], [@bib29], [@bib30], [@bib39], [@bib49], [@bib50], [@bib55]) and others ([@bib24], [@bib34], [@bib36], [@bib56], [@bib71], [@bib72]), we believe these oligomers participate in oncogenic transformation and cancer gain-of-function phenotypes. The oligomers identified in this work are formed by a chemoresistant mutant p53 present in glioblastoma tumors. It is tempting to suggest that the cellular environment limits misfolding and massive aggregation, especially by interacting with chaperones. This would lead to the formation of small oligomers that might exert gain-of-function effects. Notably, the nucleus is full of nucleic acids and especially RNAs, which were recently shown to limit p53 aggregation but facilitate small oligomer formation ([@bib35]).

The presence of M237I p53 amyloid oligomers in glioblastoma cells ([Figure 1](#fig1){ref-type="fig"}) and the nuclear M237I p53 oligomers captured in live cells ([Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}) indicate that mutant p53 destabilized conformations are present in cells and that, by evading the protein control apparatus, these aberrant p53 forms undergo oligomerization. Therefore, it is important to explore the mechanisms by which cancer-associated p53 mutations affect its folding. The polypeptide fold is extremely dependent on either its amino acid composition or the environment surroundings. The hydration of nonpolar amino acids occurs prior to amyloid aggregation and is often assessed by pressure perturbation experiments ([@bib11], [@bib12], [@bib17], [@bib54], [@bib52]). Pressure increments favor water infiltration within the protein nonpolar core, providing an opportunity to assess destabilized hydrated states ([@bib12]). Hydration effects in protein misfolding and amyloid conversion have been studied over the past 20 years in several macromolecular systems ([@bib49], [@bib55], [@bib52]). Here, the "swollen states" captured for M237I-p53 are more hydrated than those formed by wt-p53, explaining mutant sensitivity to water infiltration and the loss of structural rigidity.

The p53 fold offers an opportunity to track conformational changes by reporting the fluorescence of its Tyr and single Trp residues. In the native state, the major signal comes from the Tyr residues, whereas the single Trp residue is quenched owing to the transfer of energy between Tyr residues within the excited state. Once p53 starts to unfold, Trp quenching is lost and Trp fluorescence becomes the major contribution to the signal ([@bib8]). Furthermore, the Tyr residues within p53C (eight in total) are spread throughout the entire domain, which offers an additional advantage to map overall hydration in this case. By reporting the fluorescence of these internal probes, we have shown the origins of the destabilization of mutant p53 in solution. Furthermore, these destabilized M237I-p53 states are preamyloidogenic species in solution, as revealed by the rapid ThT kinetic traces, negative staining microscopy, and increased protein hydrophobicity in the solvent. In cell-based approaches, M237I-p53 is strongly expressed in chemoresistant glioblastoma cells under ER stress and accumulates to the same level as the amyloid species.

Although M237I is not classified as a hotspot mutation, similarities in terms of thermodynamic stability, location, and ability to disrupt DNA binding between the M237I-p53 mutant and the R175H p53 structural mutant were previously reported ([@bib8]). Using molecular dynamic simulations, we observed regions within the DNA-binding domain of wt-p53 and the hotspot R175H-p53 mutant with an elevated incidence of exposed backbone hydrogen bonds (BHBs) compared with those of the p53 family members p63 and p73 ([@bib10]). Protection of BHBs is an important feature of structural stability and the ability to form amyloid assemblies ([@bib16]). Hydrophobic shielding of BHBs may reduce hydration by preventing the interaction of labile bonds with water molecules. In the case of M237I-p53, movement of the Ile side chain away from the Zn^2+^-binding motif may expose labile BHB sites for hydration. We did not investigate the effects of the M237I-p53 mutation on Zn^2+^ displacement, but the related R175H hotspot mutation accelerates the rate of Zn^2+^ loss ([@bib9]). Notably, underprotected BHBs, also called dehydrons, act as sites for water attack, promote amyloid formation, and can be used as a strategy to target aggregation ([@bib1], [@bib68]). Recently, we have been pursuing different strategies to prevent p53 aggregation ([@bib18], [@bib49], [@bib50], [@bib55]). More importantly, the M237I mutation is fairly close to the previously identified underprotected BHB regions, reinforcing the role of hydration in p53 amyloid aggregation ([@bib10]). We believe that this mutation disturbs the fragile wt-p53C structure by increasing hydration and protein hydrophobicity to the solvent. If increased hydration proves to be common to other destabilized p53 mutations, p53 dehydrons may be used as an alternative platform to avert the gain-of-function phenotype of oligomeric p53 compositions.

Limitations of the Study {#sec3.1}
------------------------

Caveats of this work include the absence of isogenic cell lines in our experiments and testing the chemoresistant p53 mutation in other cancer cells to directly attribute the chemoresistance phenotype to aggregated p53 species. Another drawback is that we are not able to certify whether the oligomeric states captured by the N&B analysis present the typical features of amyloids.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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